2022.09-2026.06 四川大学 博士
研究方向：可解释性AI在药物设计中的应用
代表性论文
- Zhang R, Su K, Yang L, et al. Design, synthesis, and biological evaluation of novel P2X7 receptor antagonists for the treatment of septic acute kidney injury. J Med Chem. 2023, 24;66(16):11365-11389. 第一作者，中科院1区top期刊，IF=6.8
- Zhang R, Su K, Yang L, et al. Discovery of a Potent, Orally Active, and Long-Lasting P2X7 Receptor Antagonist as a Preclinical Candidate for Delaying the Progression of Chronic Kidney Disease. J Med Chem. 2024;67(19):17472-17496. 第一作者，中科院1区top期刊，IF=6.8
- Zhang R, Rao Q, Jiang X, Ye N, et al. Exploring the Immunomodulatory Properties of Red Onion (Allium cepa L.) Skin: Isolation, Structural Elucidation, and Bioactivity Study of Novel Onion Chalcones Targeting the A2A Adenosine Receptor. J Agric Food Chem. 2023 Nov 6. 第一作者，中科院1区top期刊，IF=6.2
- Zhang R, Li N, Zhao M, Tang M, et al. From lead to clinic: A review of the structural design of P2X7R antagonists. Eur J Med Chem. 2023, 5;251:115234. 第一作者，中科院1区，IF=5.9
- Zhang R, Hong F, Zhao M, et al. New highly potent NLRP3 inhibitors: furanochalcone velutone F analogues. ACS Med. Chem. Lett. 2022, 13(4):560-569. 第一作者，中科院2区，IF=4.0
- Li N, Zhang R, Tang M, et al. Recent Progress and Prospects of Small Molecules for NLRP3 Inflammasome Inhibition. J Med Chem. 2023, 9;66(21):14447-14473. 共同第一作者，中科院1区top期刊，IF=6.8
- Li N, Jiang X, Zhang R, Ye N, et al. Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis. J Med Chem. 2023, 12;66(19):13428-13451. 共同第一作者，中科院1区top期刊，IF=6.8
专利
- 叶昊宇，张芮佳，苏凯月，马良；一种P2X7受体抑制剂；专利号：ZL 2022 1 0988191.1
- 吴文爽，张芮佳，叶昊宇；一种天然查尔酮衍生物及其制备方法和用途；专利号：ZL 2020 1 1584817.X
- 叶昊宇，张芮佳，苏凯月，马良；吴文爽；P2X7R拮抗剂；国际申请号：PCT/CN2024/137672
- 叶昊宇，张芮佳，苏凯月，马良，吴文爽；一种P2X7受体拮抗剂；发明专利申请公布号：CN118184647A
